Diridavumab
Diridavumab
Diridavumab (pronounced: di-ri-da-vu-mab) is a monoclonal antibody designed for the treatment of Ebola virus disease. It is one of the three monoclonal antibodies that make up the ZMapp treatment.
Etymology
The name "Diridavumab" is derived from the Latin "diri", meaning "fearful" or "terrible", and "davumab", a common suffix for monoclonal antibodies. This reflects its use in treating the deadly Ebola virus.
Usage
Diridavumab is used in combination with two other monoclonal antibodies, c13C6 and c2G4, to form the ZMapp treatment. This combination has been shown to be effective in treating Ebola virus disease in non-human primates and has been used in humans under emergency protocols.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells. They are used in cancer treatment and other diseases.
- Ebola virus disease: A severe, often fatal illness in humans caused by the Ebola virus. It is transmitted to people from wild animals and spreads in the human population through human-to-human transmission.
- ZMapp: An experimental treatment for Ebola virus disease made up of three monoclonal antibodies.
- c13C6 and c2G4: The other two monoclonal antibodies that make up the ZMapp treatment.
External links
- Medical encyclopedia article on Diridavumab
- Wikipedia's article - Diridavumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski